Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone.

Petr VokurkaAndrew BarronSheetal SumariaLindsey StockfordPaul JarmanKailash P BhatiaSimon FarmerTabish SaifeeTom WarnerRimona Sharon WeilSonia GandhiPatricia LimousinPrasad KorliparaThomas Foltynie

Published in: Movement disorders clinical practice (2020)

We conclude that opicapone can be an effective additional treatment for wearing off in Parkinson's disease (PD) in a subgroup of patients. The use of opicapone in our cohort with prior entacapone exposure, however, was associated with higher rates of adverse effects and treatment discontinuation than reported in published trial data of COMT inhibitor naïve patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
emergency department
machine learning
patient reported
adverse drug
smoking cessation
deep learning
phase ii